Last-Resort drug teclistamab made available for desperate myeloma patients
NCT ID NCT05161598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides pre-approval access to teclistamab for people with relapsed or refractory multiple myeloma who have no other treatment options left. Participants must have tried and failed all standard therapies, including proteasome inhibitors, IMiDs, and anti-CD38 antibodies. The goal is to offer a potential treatment option when no others are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact